Pharmasset: Clinical Trials

8 trials sponsored by Pharmasset, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 terminated. 3 Phase 1, 3 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3
Phase 23Completed 3
Phase 33Terminated 3

Follow Pharmasset: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
PSI-7977, Daclatasvir, Ribavirin - Chronic Hepatitis C
Phase 2CompletedBristol-Myers Squibb3502011-06-012015-10-23
ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy
CLEVUDINE + TENOFOVIR PLACEBO, CLEVUDINE IN ASSOCIATION TENOFOVIR, TENOFOVIR + CLEVUDINE PLACEBO - HBe Negative Chronic Hepatitis B, Hepatitis B Viral Infection
Phase 3TerminatedFrench National Agency for Research on AIDS and Viral Hepatitis1502008-12-142026-04-06
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
Clevudine, Adefovir - Chronic Hepatitis, Hepatitis B
Phase 3TerminatedPharmasset2007-08-012009-04-27
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
Clevudine, Adefovir - Chronic Hepatitis, Hepatitis B
Phase 3TerminatedPharmasset2007-08-012009-04-27
Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin
RO5024048 - Healthy Volunteers, Hepatitis C Virus
Phase 1 / Phase 2CompletedPharmasset752006-10-012009-04-27
Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects
Racivir, a non-nucleoside reverse transcriptase inhibitor - HIV Infections
Phase 2CompletedPharmasset602004-09-012007-07-03
A 14-Day Study of Racivir When Used in Combination in HIV-Infected Males
Racivir - HIV Infections
Phase 1CompletedPharmasset182002-06-012005-07-21
A Study of DPC 817 in HIV-Infected Males
DPC 817 - HIV Infections
Phase 1CompletedPharmasset302005-07-19

Conditions studied

HIV Infections (3)  ·  Hepatitis B (3)  ·  Hepatitis, Chronic (2)  ·  Hepatitis (1)  ·  Hepatitis C (1)  ·  Hepatitis C, Chronic (1)

Interventions

clevudine (3)  ·  Racivir (2)  ·  adefovir (2)  ·  Ribavirin (1)  ·  Sofosbuvir (1)  ·  Tenofovir (1)  ·  daclatasvir (1)  ·  dexelvucitabine (1)

Countries

United States (6)  ·  Puerto Rico (4)  ·  Argentina (3)  ·  Australia (2)  ·  Canada (2)  ·  China (2)  ·  Greece (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Thailand (2)  ·  United Kingdom (2)  ·  Brazil (1)  ·  France (1)  ·  Germany (1)  ·  Mexico (1)

Top investigators

M Michelle Berrey, MD, MPH (1)  ·  M. Michelle Berrey, MD (1)  ·  M. Michelle Berrey, MD, MPH (1)  ·  Robert Murphy, MD (1)

Results publications

PMID 24428467

NIH funding

2008 (1)